Braeburn is a pharmaceutical company dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid addiction. The company's mission is to advance a portfolio of next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of addiction faced by patients, healthcare professionals, payers and society.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/11/18 | $110,000,000 | Mezzanine |
Apple Tree Partners Avista Capital Holdings Deerfield Management Company, L.P. New Leaf Venture Partners RA Capital Management Rock Springs Capital Wellington Capital Management  | undisclosed |
